FDA cleared the cobas eplex respiratory pathogen panel 3 from GenMark Diagnostics, Inc. on Oct 30, 2026 under K262938, a traditional 510(k). The device falls under product code QOF, Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents, regulated at 21 CFR 866.3981 as a Class 2 device. The review panel was Microbiology.
FDA logged the submission as received on Aug 21, 2026. The decision came 70 days later, inside the 90 FDA-day goal for a 510(k).
This is the only decision on file for GenMark Diagnostics, Inc. in the last 12 months of the tracker.
Questions & Answers
What did FDA clear under K262938?
K262938 is the FDA 510(k) for cobas eplex respiratory pathogen panel 3, submitted by GenMark Diagnostics, Inc.. FDA's decision date was Oct 30, 2026, under product code QOF (Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents).
Who makes the cobas eplex respiratory pathogen panel 3?
GenMark Diagnostics, Inc., based in Carlsbad, CA, is the applicant of record for K262938.
How long did the K262938 review take?
FDA received the submission on Aug 21, 2026 and issued its decision on Oct 30, 2026, 70 days later.